☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receives the US FDA’s Approval of Elfabrio (pegunigalsidase alfa-iwxj) fo...
May 10, 2023
PharmaShots Weekly Snapshots (May 01 - 05, 2023)
May 5, 2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) fo...
May 5, 2023
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EMA’s CHMP Positive Opinion of Pegunigalsidase Alfa for Fabry Dis...
March 20, 2023
Chiesi Global Rare Diseases Receives the US FDA’s Approval of Lamzede (velmanase alfa-tycv) for Alpha-Mannosidosis
February 16, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.